Acadia Pharma (ACAD): 2Q Results Don't Capture A Real Indication For NUPLAZID Demand - Piper Jaffray
Go back to Acadia Pharma (ACAD): 2Q Results Don't Capture A Real Indication For NUPLAZID Demand - Piper Jaffray| Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) | Delayed: 27.34 -0.2 (0.73%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $27.54 | 52 Week High | $42.49 | |||
| Open | $27.78 | 52 Week Low | $16.64 | |||
| Day High | $28.06 | P/E | N/A | |||
| Day Low | $27.29 | EPS | $-0.42 | |||
| Volume | 726,639 | |||||
